Cancer Research Institute - Cancer ImmuNews - Vol. 3, Issue 1

CRI Homepage > Resources & Publications > News & Reports > E-Newsletter > Cancer ImmuNews (3:1) August 2010

Volume 3, Issue 1

August 2010

IN THIS ISSUE

Unmasking Cancer:
New Directions in Colorectal Cancer Research

CRI Leader in the Field:
Vincenzo Cerundolo Named to Top Position in U.K. Immunology Research Group

Recent Announcements:
Milestones in tumor immunology, CRI symposium, new publications

QUICK LINKS

CRI Homepage

Donate to CRI

Subscribe to Cancer ImmuNews

GIVE WISELY

CRI consistently earns top marks from leading charity watchdogs.

SHARE CRI's STORY

Help the cause by forwarding this email to three of your friends. Be sure to tell them why you support our work.

Don't forget to do all your
online holiday shopping with GoodShop.com to benefit CRI

STAY IN THE KNOW

Subscribe to our other free channels to get CRI updates & cancer news:

Thank you for your support.

Unmasking Cancer: new directions in colorectal cancer research

Colorectal cancer is the fourth most common cancer and the second-leading cause of cancer death in the United States. A Cancer Research Institute scientist is studying a new treatment approach that may help to make this type of cancer more vulnerable to attack by our immune system.

If successful, this new approach may open up new treatment options for colorectal cancer patients who currently may not benefit from the new class of immune system-based treatments CRI scientists are working to develop.

Unmasking Cancer >>

CRI scientist named to top position in U.K. immunology research group

The Medical Research Council (MRC), a publicly funded U.K. organization dedicated to improving human health, has announced that CRI scientist Vincenzo Cerundolo, M.D., Ph.D., has been named director of the MRC Human Immunology Unit (HIU) at the John Radcliffe Hospital in Oxford, U.K.

CRI Leader in the Field >>

Recent Announcements

Ipilimumab, a new immunotherapy discovered and tested by CRI scientists, is proven to extend life for patients with metastatic melanoma.

Breakthrough New Melanoma Treatment >>

Provenge cancer vaccine approved by FDA for treatment of late-stage prostate cancer, making it the first FDA-approved therapeutic cancer vaccine.

Prostate Cancer Vaccine >>

Symposium 2010, the 18th CRI Annual International Cancer Immunotherapy Symposium, will take place Oct. 6-8, 2010, in New York City. Register today.

Register for the CRI Symposium >>

New Publication: The Researcher, CRI's 12-page printed newsletter, is now available online.

Read The Researcher >>

New Publication: Visionary, the newsletter providing financial and gift planning ideas for friends of the Cancer Research Institute, is now available online.

Read Visionary >>

Forward this message to a friend | Phone: (212) 688-7515 or Toll-free (800) 99-CANCER